
LC-MS Analysis Service of Recombinant Antibodies
We have entered a service agreement with evitria AG (Zürich, Switzerland) to offer a fast and high-quality LC-MS characterization of recombinant antibodies using our SmartEnzymes™ workflows!
Thanks to the ease of use of SmartEnzymes in combination with the competence and experience in our team, advanced LC-MS analysis is now available to a broader market. Being the market-leading service provider for recombinant antibody expression in CHO cells, evitria AG is a perfect partner for us in our ambition to expand our service offering!
The agreement is a starting point for us to offer automated LC-MS analytical services with fast turnaround times to customers within the biopharmaceutical industry. The trend to outsource R&D activities continues to grow, and with our smart and fast sample preparation workflows, we can provide a high-quality LC-MS characterization in just a few days. More information about our LC-MS Analysis Service will be available on our webpage shortly, so keep your eyes open! If you have questions, you are welcome to send an email with your inquiry to jonathan.sjogren@genovis.com.
“Our transient expression service is designed to provide the highest quality material within the shortest timeframe possible. The SmartEnzymes workflow from Genovis perfectly complements this approach by providing valuable insights from LC-MS analysis with rapid turnaround times. We cannot wait to offer this to the market, and empower researchers with the combination of our technologies“, says Christian Eberle, CEO at evitria.
“By offering the SmartEnzymes workflow as a service to antibody developers, we demonstrate our fast and robust sample preparation technologies that allows for easy interpretation of advanced LC-MS antibody characterization data. The quality and speed of the automated recombinant antibody services provided by evitria makes them a perfect partner for us to expand our service offering and we are excited to team up with one of the leaders in this field”, says Fredrik Olsson, CEO at Genovis.
Read the Press Release.
Learn more about our SmartEnzymes for Antibody Digestion.